News

The first domestic teriflunomide tablets were sold on the market, and the drug security for rare diseases ushered in new hope

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-08-10
  • Views:0

(Summary description)Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

The first domestic teriflunomide tablets were sold on the market, and the drug security for rare diseases ushered in new hope

(Summary description)Today, the first domestic teriflunomide tablets developed by Shengshi Tyco are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-08-10
  • Views:0

Today, the first domestic teriflunomide tablets developed by CGeneTech are on sale. The first batch of patients will benefit Beijing, Shanghai, Guangzhou, Chengdu, Suzhou and other core cities. The follow-up will soon cover the national market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.


Multiple sclerosis (MS) is a lifelong, chronic and progressive disease. More than 2.3 million people worldwide suffer from multiple sclerosis, and nearly 50000 patients in China. In May 2018, multiple sclerosis was included in the first list of rare diseases in China. Its etiology originates from the pathological changes of the autoimmune system, causing the damage and peeling of the nerve myelin sheath, resulting in the damage of the spinal cord, brain and optic nerve functions. The patient's nervous system disability gradually worsens, and the patient loses self-care ability, blindness and even life. Early diagnosis and treatment are required.

Teriflunomide is an immune modulator with anti-inflammatory effect. It has definite efficacy and good safety when taken for a long time. It is the first-line drug recommended by domestic and foreign guidelines for the treatment of multiple sclerosis. The telifloxamine tablets developed by CGeneTech passed the consistency evaluation with the original drugs. The marketing broke the current situation of excessive dependence on imported drugs for the treatment of multiple sclerosis. It will significantly improve the drug availability of domestic patients, ensure the continuity of drug supply, and not be affected by various overseas factors.

Dr. Yu Qiang, founder and CEO of CGeneTech, said: "In fact, rare diseases are not rare. But there is no medicine to cure, which is the unspeakable pain of patients with rare diseases. The earlier the diagnosis and treatment of multiple sclerosis are, the better the symptoms can be alleviated and the development of the disease can be delayed. Therefore, today we are glad to see that the terfloxacin tablets produced by CGeneTech are sold on the market, benefiting domestic patients and making every small group no longer give up. In the future, the company will focus on the unmet needs of China and the world Guided by clinical needs, we will develop innovative drugs with high accessibility and better efficacy to benefit patients worldwide. "

Founded in Suzhou Industrial Park in 2010, CGeneTech is committed to the R & D and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R & D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as glucose lowering, anticancer and rare diseases. Among them, the original hypoglycemic new drug Cetagliptin phosphate has entered the final stage of clinical phase III, which is expected to fill the gap of domestic original DPP-4 inhibitors; Three of the anticancer drugs under research have entered the clinic. The FGFR / VEGFR dual target inhibitor cgt-6321 has been carried out in phase I clinical trials in advanced solid tumors, and this drug is expected to become a potential first in class drug; CXCR4 antagonist cgt-1881 is used for hematopoietic stem cell mobilization, and oral administration is more convenient; Cgt-9475, a new generation ALK / ret inhibitor, is expected to solve several major clinical pain points such as drug resistance and brain metastasis in the treatment of lung cancer. Both of the latter two projects have obtained the clinical approval of the US FDA, which has taken a solid step in the company's innovative drugs going to sea.

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO